Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease

N/ATerminatedNCT00801268

Zhi-Hong Liu, M.D.300 enrolled

Overview

Triptolide has been approve effective in animal model.

Randomized

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

300

Conditions

Polycystic Kidney

Interventions

tripterygium wilfordiiDRUG

TW，60mg/d

EmodinDRUG

100mg/d

Eligibility

Sex: ALLMin age: 15 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinically established ADPKD * eGFR\>30ml/min. * Chinese nationality Exclusion Criteria: * Uncontrolled infections * Non-ADPKD complications

Locations (2)

Liu ZH, Yao XD,Chen X,Hu YL

Nanjing, Jiangsu, China

Yao Xiaodan

Nanjing, Jiangsu, China

Outcomes

Primary Outcomes

MRI calculated kidney volume, eGFR

Time frame: Every 3-6months

Secondary Outcomes

End-stage kidney disease (ESRD)

Time frame: every 2months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.